Brind.

Krystal Biotech, Inc. focuses on genetic medicines in the US.

5 reports, 4 independent Updated Aug 1
Gone quiet Reached 3 outlets in its first 24 hours
Reports
5
Developments
6
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 4 independent outlets

Krystal Biotech, Inc. focuses on genetic medicines in the US.

Who's involved

What this event is mainly about
Krystal Biotech, Inc.

How it developed

Newest first. Tap a step to see who reported it.
  1. Krystal Biotech confirmed its base in Pittsburgh and reported U.S. uptake.1 source
  2. Krystal Biotech, Inc. reached out to the FDA following promising early evidence.Sub-event
  3. Krystal Biotech focuses on genetic medicines in the US.1 source
  4. Krystal Biotech's VYJUVEK drug received approval in Japan.1 source
  5. KB707 showed promising early efficacy in NSCLC, while Vyjuvek is a core genetic therapy.1 source
  6. Krystal Biotech, Inc. expects significant growth driven by upcoming product launches in Europe and Japan.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • ibtimes.com.au
  • Simply Wall St.High Growth Tech Stocks In US For September 2025 As September 2025 begins, the U.S. market is experiencing a downturn, particularly in the tech sector, with key indices like the S&P 500 and Nasdaq Co
  • GlobeNewswireKrystal Biotech to Present at Cantor Global Healthcare Conference 2025 PITTSBURGH, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Com
  • Simply Wall St.Does Inhaled KB707’s Progress Signal a New Chapter for Krystal Biotech’s (KRYS) Pipeline Strategy? Earlier this month, Krystal Biotech announced an update on its KB707 program, sharing promising earl
  • GuruFocus.comKrystal Biotech Inc (KRYS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... Net VYJUVEK Revenue: $96 million for Q2 2025. Total Net VYJUVEK Revenue Since Launch: Over $525 million. Gro